AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05899933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical peri-implant therapy
Description: 2 weeks after baseline examination, non surgical therapy will be applied in implants diagnosed with peri-implantitis prior to enrollment in surgical therapy.~Firstly, participants will be instructed in oral hygiene. Professional supragingival and subgingival debridement of implants/ teeth, including the selected for the study implants, will be performed. Local anesthesia will be performed, when needed. Targeted implants will be treated with PEEK-coating ultrasonic tips (Instrument PI; EMS), titanium curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy), rubber cup and polishing paste. Possible adjustments to implant-borne prostheses will be considered, whenever possible. Re-evaluation of non-surgical therapy will be performed after 6 weeks.~At the 6-week reevaluation, participants with peri-implant probing pocket depth ≥5 mm and bleeding on probing and/or suppuration in patients with full mouth plaque score ≤20% will proceed to surgical therapy.
Study NCT05899933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantoplasty
Description: Screw-retained supraconstructions and, when possible, cement-retained restorations will be removed.~Following local anesthesia, intrasulcular incisions will be performed and full-thickness flaps will be elevated on the buccal and lingual aspects of affected implants. Granulation tissue will be removed, and titanium-coated curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy) and NiTi brushes (NEGRIN IN DENTAL) will be applied to remove hard deposits on implants. Osseous recontouring will be performed when indicated followed by irrigations with saline. Implantoplasty will be applied using tungsten carbide burs of various shapes and sizes (Peri-implantitis Kit; Meisinger) followed by irrigations with saline. Flaps will be readjusted and closed with sutures in order to allow a non-submerged healing. Supraconstructions will be reconnected after the surgery.
Study NCT05899933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erythritol Air-abrasive device
Description: Screw-retained supraconstructions and, when possible, cement-retained restorations will be removed.~Following local anesthesia, intrasulcular incisions will be performed and full-thickness flaps will be elevated on the buccal and lingual aspects of affected implants. Granulation tissue will be removed, and titanium-coated curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy), and NiTi brushes (NEGRIN IN DENTAL) will be applied to remove hard deposits on implants. Osseous recontouring will be performed when indicated followed by irrigations with saline. Implant surface decontamination with an air-abrasive device (AIRFLOW® MAX, AIRFLOW® Prophylaxis Master; EMS) with erythritol powder (AIRFLOW® Plus Powder; EMS) will be applied followed by irrigations with saline. Flaps will be readjusted and closed with sutures in order to allow a non-submerged healing. Supraconstructions will be reconnected after the surgery.
Study NCT05899933 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prophylaxis
Description: Supramucosal biofilm removal of implants/ teeth will be performed at, 3, 6, 9 and 12 months after surgical therapy for the Implantoplasty group and the Erythritol Air-abrasive device group and at 2 weeks, 3, 6, 9 and 12 months after baseline examination for the control group. Targeted implants will be treated with an air-abrasive device (AIRFLOW® MAX, AIRFLOW® Prophylaxis Master; EMS) with erythritol powder (AIRFLOW® Plus Powder; EMS). During these appointments, patients will be re-motivated and re-instructed to oral-hygiene measures.
Study NCT05899933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylaxis
Description: Supramucosal biofilm removal of implants/ teeth will be performed at, 3, 6, 9 and 12 months after surgical therapy for the Implantoplasty group and the Erythritol Air-abrasive device group and at 2 weeks, 3, 6, 9 and 12 months after baseline examination for the control group. Targeted implants will be treated with an air-abrasive device (AIRFLOW® MAX, AIRFLOW® Prophylaxis Master; EMS) with erythritol powder (AIRFLOW® Plus Powder; EMS). During these appointments, patients will be re-motivated and re-instructed to oral-hygiene measures.
Study NCT04989790 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PICU Up!
Description: PICU Up! incorporates the screening process for determining a patient's appropriate activity level into the daily rounding workflow for all PICU patients, with a tiered activity plan based on clinical parameters to individualize goals based on each child's unique needs. While the patient's PICU Up! level is based on objective criteria, the interprofessional team collectively determines the daily activity goal(s) through shared decision-making which is documented in the medical record on morning rounds. The intervention facilitates daily discussion of 1) analgesia; 2) extubation readiness testing; 3) sedation level and goal; 4) delirium screening and management; 5) mobility goal including physical and occupational therapy consultation by PICU Day 3; 6) sleep promotion; and 7) family engagement in mobility.
Study NCT05071937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEN003694
Description: ZEN003694 has shown promising activity in the treatment of solid tumors and hematologic (blood) cancers by reducing the multiplication of cancer cells.
Study NCT05071937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib kills cancer cells by inhibiting and trapping the enzyme PARP, which is known to be involved in the development of many types of cancers.
Study NCT06390241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avidin-biotin-Dota-90Y
Description: Within 7-8 days after the VABB procedure, 6-10 mg avidin in 1 ml saline will be administered at the site of the occult carcinoma. Subsequently, 90Y DOTA-biotin in the range of 28-57-126 MBq (3 activity levels investigated) will be injected locally immediately after avidin injection.
Study NCT05229692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEUBIE
Description: Participants will be asked to undergo electrical stimulation with the NEUBIE at their treatment threshold. Treatment threshold will be described as uncomfortable, but not painful (a 7 out of 10 on a perceived intensity scale).~Session length: ≤ 30 minutes Treatment frequency: 2x per week for 5 weeks~Week 1 post-op (treatments 1-2) Activity: Passive Neubie on Abdominals \& Obliques~Weeks 2-3 (treatments 3-6)~* Passive Neubie~* Isometric movements with Neubie on abdominals and obliques~* Active mobilizations with Neubie on abdominals and obliques~Weeks 4-5 (treatments 7-10)~* Active mobilizations with Neubie on abdominals and obliques~* Core Strength Exercise circuit with Neubie on abdominals and obliques
Study NCT06427772 — intervention group
Intervention type: PROCEDURE
Intervention: bipolar hemiarthroplasty
Description: bipolar hemiarthroplasty for neck femur fracture
Study NCT06558994 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transection of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis
Description: Half of the patients will undergo transection of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis.
Study NCT06558994 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ligation of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis
Description: Half of the patients will undergo ligation of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis
Study NCT05952804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Infusion (Human), 10% Solution
Description: Given IV
Study NCT06585683 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory Evaluation at Day 4
Description: Peripheral blood samples, including serum, PBMC, and whole blood, are collected from participants. A tongue swab is also collected from each participant.
Study NCT06585683 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Evaluation at week 26
Description: Participants will undergo another complete physical exam and have their medical (including TB) history, potential TB signs/symptoms, and concomitant medications reassessed. Chest radiography will be obtained for all participants. An assessment of TB outcomes will also be performed.
Study NCT06585683 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory Evaluation at week 26
Description: Peripheral blood samples, including serum, PBMC, and whole blood, will be collected. Participants not previously identified as living with HIV will undergo HIV diagnostic testing, while participants living with HIV will have their HIV viral load and CD4+ T-cell count measured.
Study NCT05952804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR T Cells Preparation
Description: Given CAR-T treatment
Study NCT05952804 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Anti-CD19 CAR T Cells Preparation
Description: Given CAR-T treatment
Study NCT05952804 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Given IV
Study NCT05952804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05952804 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05952804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05952804 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05952804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT05952804 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT03759405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iPS differentiated cardiomyocytes
Description: Repair of injured myocardium by vein transplantation with autologous iPS differentiated cardiomyocytes
Study NCT06147102 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgical treatment for the unruptured intracranial aneurysm
Study NCT06147102 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular
Description: Endovascular treatment for the unruptured intracranial aneurysm
Study NCT06585280 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06584864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bedside ultrasound examination of the lumbar spinal canal
Description: The ultrasound examination will be performed using a Lumify linear probe (frequency range 4-12 MHz). In the longitudinal projection, the doctor will assess the spinal cord endings by marking them with a sterile marker - a horizontal line on the patient's back. In the same projection, the doctor will designate a safe and optimal place (the greatest width of the dural sac) for performing a lumbar puncture by marking it with a sterile marker. Additionally, in the longitudinal projection, the researcher will measure the depth from the skin surface to the dura mater. Then, in the transverse projection, the doctor will confirm the absence of the spinal cord at the planned puncture site and the optimal amount of cerebrospinal fluid in the selected space. This information will be passed on to the operator, who will ultimately decide on the lumbar puncture site.
Study NCT05737524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (VAST 2)
Description: The telehealth platform will be available by a web secure link accessible on a home computer or loaded on user friendly tablets that are customized for the patient's impairments. Telerehabilitation services will include 2 out of 3 disciplines: Occupational Therapy, Speech Therapy, Physical Therapy. All therapy interventions will be delivered by licensed therapists and will be based on patients' specific impairments and goals. Therapy intervention will be provided 3x/wk. for each of 2 disciplines. The intervention will be going on for 4 weeks which will total to 24 sessions. Self-management support with trained health coach will be integrated into 1 therapy session each week. An additional individual 30 minute session will occur with the health coach each week.
Study NCT06194110 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ergometric test
Description: Ramp test followed by a step test, both with ergospirometry
Study NCT06642324 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Histopathology, Immunohistochemistry, Real-Time PCR, Sequencing
Description: Histopathology for carcinoma detection, Immunohistochemistry for carcinoma-related protein expression, Real-Time PCR for HPV association and HPV typing, Sequencing for genetic study or mutation analysis.
Study NCT06532630 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Anti-CD19-CAR-T cells
Description: Each subject will be infused with single dose of anti-CD19-CAR-T cells.~A classic 3+3 dose escalation will be employed.
Study NCT06532630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be given at a dose of 25 mg/m2/day intravenously (IV) for 3 days prior to anti-CD19-CAR-T cells infusion.
Study NCT06532630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be given at a dose of 250 mg/m2/day intravenously (IV) for 3 days prior to anti-CD19-CAR-T cells infusion.
Study NCT04695223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: Refractory cancer patients without standard-of-care harboring TP53 mutation received Arsenic Trioxide Injection (0.16mg/kg,d1-5,ivgtt,28days as a duration)
Study NCT05752149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRGD-ZW800-1
Description: Intravenous administration of study drug at lesat 2h prior to surgery
Study NCT05117502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent Theta Burst Stimulation
Description: intermittent Theta Burst Stimulation (iTBS) is a type of repetitive transcranial magnetic stimulation (rTMS), which uses short magnetic field pulses applied to the scalp to induce currents in the underlying brain. iTBS will be delivered by the MagVenture MagPROX100 with MagOption Stimulator and MagPro Cool Coil B65 A/P. The MagPro Cool Coil B65 A/P can be switched from active to placebo.
Study NCT05117502 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intermittent Theta Burst Stimulation
Description: The placebo coil magnetic stimulation, but does not actually emit a pulse. The placebo coil looks, sounds and feels like an active iTBS coil. The placebo coil, visually identical to the active coil, provides a slight sensory sensation and discharge noise (i.e. clicking) nearly identical to that of the active coil.
Study NCT05282992 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Native type II collagen
Description: 1 capsule/day
Study NCT05282992 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule/day
Study NCT05228600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL-13027
Description: YL-13027 is a novel small molecule TGF-βR1 inhibitor. 1.1.1. Chemical Properties~Chemical Name:~6-(5-fluoro-2-(6-methylpyridin-2-yl)phenyl)imidazo\[1,2-a\]pyridine-3-carboxamide Molecular Formula C20H15FN4O Molecular Weight 346.36 Formulation YL-13027 is provided as pink film coated tablets for oral administration in two strengths, 30 mg and 120 mg.~Packaging and Storage YL-13027 tablets are packaged (30 tablets/bottle) in the 45 mL opaque HDPE bottles with child resistant polypropylene caps, induction-sealed inner polypropylene liners. YL-13027 tablets should be protected from light in a closed container and stored at room temperature.~Stability The shelf-life of YL-13027 oral tablets is tentatively set at 24 months when stored at room temperature.
Study NCT06053333 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT06256952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PIT paradigm
Description: The paradigm consists of four parts:~In the first part, an instrumental learning task is completed in which subjects must learn which stimuli require a response and which do not. In the second part, a classical (Pavlovian) conditioning task is then completed in which subjects learn by passive viewing which stimuli are associated with certain amounts of money. The third part measures to which instrumental responses (learned in Part 1) are modulated by the presentation of the classically conditioned stimuli (learned in Part 2). At the same time drug-associated stimuli are presented in the background measuring to which extent they conflict with the learned instrumental behavior. In the last part, query trials are implemented in which the participants have to choose between two pictures to assess the relative cue value.
Study NCT05186623 — intervention group
Intervention type: DRUG
Intervention: Vedolizumab, Ustekinumab, or Tofacitinib
Description: Drug administration and prospective follow-up for evaluating response
Study NCT06256952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social exclusion (Cyberball task)
Description: Social exclusion will be assessed using the cyberball paradigm: subjects will play an online game tossing a ball to each other with two more virtual co-players. Using a cover story, we make subjects believe that the co-players really exist and that they play a live online game. During social exclusion, subjects will be systematically excluded by one co-player, and during social inclusion, ball tosses will be balanced between all three players.
Study NCT06256952 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saliva samples
Description: Assessing acute stress effects in AUD and HC subjects
Study NCT06256952 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: basic psychological assessment
Description: * Sociodemographics~* ASSIST~* Quantity Frequency: Alcohol, tobacco/e-cigarette, Cannabis \& other illegal drugs~* SCID: AUD criteria and tabak use disorder life time and last year \& acute depressive symptoms \& symptoms for Mania and psychotic disorder~* Edinburgh Handedness Inventory (EHI)~* Fagerström Test for Nicotine depend (FTND)~* Barratt Impulsiveness Scale - Kurzversion (BIS-15)~* Allgemeine Depressionsskala (ADS)~* State-Trait-Anxiety Inventory (STAI-T)~* Alcohol Use Disorders Identification Test (AUDIT)~* Cannabis Use Disorder Identification Test (CUDIT)~* CAS -A (Alkohol)~* Fragebogen zur Sozialen Unterstützung (F-SozU K-14)~* Oslo-3-Items-Social-Support Scale~* Social Skills Rating System (SSRS)~* Trier Inventory for chronic stress (TICS)~* Rejection Sensitivity Questionnaires (RSQ-9)~* Need to belong scale (NTBS)~* Fragebogen zu Gedanken und Gefühlen (FGG-14)~* Internationale Trauma Questionnaire (ITQ)~* Zahlen-Symbol-Test (DST)~* Wortschatztest (verbal intelligence)
Study NCT04873570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: Moxifloxacin 400mg IR tablet
Study NCT04873570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg
Description: Moxifloxacin 400mg IR tablet
Study NCT06256952 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pre and post cyberball task
Description: Positive and Negative Affect Schedule(PANAS)
Study NCT05983822 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Technological Group
Description: Specific rehabilitation for the recovery of hand function using the end-effector robot
Study NCT05983822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technological Group
Description: Specific rehabilitation for the recovery of hand function using the end-effector robot
Study NCT05983822 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Conventional rehabilitation
Study NCT05812001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergames-acceptance and commitment therapy (e-ACT)
Description: In the e-ACT training program, participants will perform a 30-minute per session Nintendo-program on TV for three days per week and a 50-minute ACT session per week for 8 weeks which will take place in the psychology labs of AMDI, USM. The ACT session will be held after 30 minutes break following the completion of the final exergame session of the week. Hence, the total duration of each weekly e-ACT training session will be approximately 2 hours. In addition, each weekly e-ACT training session will be held at the same time (± 2 hours) and at the same venue.
Study NCT05812001 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and commitment therapy (ACT)
Description: As for the ACT intervention, each ACT session will run for 50 minutes, one session per week for 8 weeks. Each weekly ACT session will be held at the same time (± 2 hours) and at the same venue (in the psychology lab).
Study NCT06256952 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VAS
Description: subjective arousal, subjective stress, valence, perceived ostracisms/loneliness
Study NCT05334862 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 8 plate hemiepiphysiodesis
Description: surgical procedure by lateral incision in proximal tibia and distal femur and fixation by using 8 plate and screws.
Study NCT06256952 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: after cyberball task
Description: * Need Threat Scale~* Manipulation check (VAS scale)
Study NCT05316441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducation
Description: Positive Psychotherapy is a recently emerged therapy method that works on talents. In the study, success skill development psychoeducation based on positive psychotherapy will be applied.